复星医药自研1类肺癌创新药复瑞替尼上市申请获受理

Core Viewpoint - Fosun Pharma announced that its self-developed first-class new drug, Foritinib (SAF-189), has recently been accepted for listing application by the National Medical Products Administration of China [1] Group 1: Drug Information - Foritinib is primarily used for the treatment of ALK-positive non-small cell lung cancer (NSCLC) and ROS1-positive NSCLC [1] - The current application is for the treatment of locally advanced or metastatic NSCLC patients who are positive for anaplastic lymphoma kinase (ALK) [1]